Jonathan Terrett
Chief Tech/Sci/R&D Officer at CRISPR THERAPEUTICS AG
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Samarth Kulkarni | M | 45 | 9 years | |
Doug Treco Treco | M | 66 | 4 years | |
Simeon George | M | 46 | 9 years | |
Ali Behbahani | M | 47 | 9 years | |
Jim Kasinger | M | 52 | 7 years | |
Maria Fardis | M | 56 | 2 years | |
Katherine High | M | 72 | 5 years | |
John Greene | M | 58 | 5 years | |
Raju Prasad | M | 40 | 1 years | |
Harold Edward Fleming | M | 61 | 3 years | |
Stephen Kennedy | M | 67 | 5 years | |
Megan Wherry Menner | F | - | 8 years | |
Alex Harding | M | - | 1 years | |
Susan Kim | F | - | - | |
Rachel Eides | F | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Rodger Novak | M | 56 | 10 years | |
Bradley Bolzon | M | 64 | 9 years | |
Pablo Cagnoni | M | 60 | 4 years | |
Michael Tomsicek | M | 58 | 4 years | |
Stuart Bradley | M | - |
The University of Nottingham
| 5 years |
Parmjit Singh Dhanda | M | 52 |
The University of Nottingham
| 6 years |
Kala Subramanian | M | 57 | - | |
Stephen Franklin | M | 56 |
The University of Nottingham
| 8 years |
Tirtha Chakraborty | M | 51 | 3 years | |
Geoff Neil | M | - |
The University of Nottingham
| 7 years |
Thomas Woiwode | M | 52 | 5 years | |
Yiu Ming Tang | M | 69 |
The University of Nottingham
| 7 years |
Kurt von Emster | M | 56 | 4 years | |
N. Coles | M | 63 | 2 years | |
Marie-Claire Peakman | F | - |
The University of Nottingham
| 7 years |
Brendan Smith | M | 48 | 2 years | |
Neil Fairfield | M | 49 |
The University of Nottingham
| 3 years |
Yong Chua Teo | M | - |
The University of Nottingham
| 3 years |
Nedal Al-Sakrat | M | 66 |
The University of Nottingham
| 1 years |
Phuong Khanh Morrow | M | 50 | 2 years | |
Adam Key | M | - |
The University of Nottingham
| 4 years |
Pavitt Simon | M | - |
The University of Nottingham
| 3 years |
Hann Ruey Lin | M | 59 |
The University of Nottingham
| 1 years |
Robert Hamlin | M | - |
The University of Nottingham
| 3 years |
Matt Harrison | M | - |
The University of Nottingham
| 1 years |
Kah Sung Chow | M | 58 |
The University of Nottingham
| 2 years |
Richard Toon | M | 53 |
The University of Nottingham
| 4 years |
Catherine Davidson | F | - |
The University of Nottingham
| 4 years |
Tom Jack | M | - |
The University of Nottingham
| 3 years |
Rewadee Jantamaneechote | M | 49 |
The University of Nottingham
| 3 years |
Nadzri Bin Yahaya | M | 67 |
The University of Nottingham
| 1 years |
Philippe Drouet | M | - | - | |
Tony Ho | M | 58 | 4 years | |
Koon Pek Ng | F | 47 |
The University of Nottingham
| 4 years |
Shelby Walker | F | - | 5 years | |
Kristina Meyer | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | 2 years |
Huey Miin Wong | F | 48 |
The University of Nottingham
| 4 years |
Stephen Lamb | M | 51 |
The University of Nottingham
| 3 years |
Andrew David Deakin | M | 51 |
The University of Nottingham
| 3 years |
Richard Schwartz | M | - | 1 years | |
Phil hinson | M | - |
The University of Nottingham
| 3 years |
Michael Denis Barker | M | 48 |
The University of Nottingham
| 4 years |
Mike Barker | M | - |
The University of Nottingham
| 3 years |
Paul Miller OBE | M | - |
The University of Nottingham
| 3 years |
Steve Howard | M | - |
The University of Nottingham
| 5 years |
Oei Wee Guan | M | 55 |
The University of Nottingham
| 3 years |
Abhinav Shukla | M | 51 | - | |
Manoj Kumar Sinha | M | - |
The University of Nottingham
| 3 years |
Jason Rogers | M | - |
The University of Nottingham
| 4 years |
Andy I. Cooper | M | - |
The University of Nottingham
| 3 years |
David Lonsdale | M | - |
The University of Nottingham
| 3 years |
Andy Davidson | M | - |
The University of Nottingham
| 3 years |
Osama Mohammed Al-Orayidh | M | 60 |
The University of Nottingham
| 1 years |
Michael Penn | M | - |
The University of Nottingham
| 4 years |
Caroline Gulliver | F | 59 |
The University of Nottingham
| 4 years |
Tessa Starmer | F | - |
The University of Nottingham
| 4 years |
Ian Osburn | M | - |
The University of Nottingham
| 4 years |
Louis Joseph Nisbet | M | - |
The University of Nottingham
| - |
Steven Caffé | M | - | 5 years | |
Stephen Vaughan | M | - |
The University of Nottingham
| 2 years |
Bryan Geoffrey Morton | M | 67 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
Michael G. Moore | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
Tyle M. Dylan-Hyde | M | 62 | 3 years | |
Jeffrey Roger Warren | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
Mark Lunn | M | - |
The University of Nottingham
| 4 years |
Fiona MacLaughlin | M | - |
The University of Nottingham
| 3 years |
Marc A. Becker | M | 52 | 1 years | |
Neville F. Rieger | M | - |
The University of Nottingham
| 4 years |
Yee Wah Chan | M | 58 |
The University of Nottingham
| 2 years |
Carl Sheldrick | M | - |
The University of Nottingham
| 4 years |
Thomas Reynolds | M | 65 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
Esteban Pombo-Villar | M | - |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
Colin Glenn Begley | M | 68 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
Andrew John Fones | M | - |
The University of Nottingham
| 4 years |
Duncan Pettigrew | M | - |
The University of Nottingham
| 3 years |
John Savill | M | - |
The University of Nottingham
| 1 years |
Hikmahanto Juwana | M | 58 |
The University of Nottingham
| 3 years |
Nicos Michaelas | M | 51 |
The University of Nottingham
| 4 years |
Edward Aston Wass | M | 53 |
The University of Nottingham
| 3 years |
Bill Lundberg | M | 60 | 3 years | |
Sarah Thompson | F | - |
The University of Nottingham
| 4 years |
Norita binti Ja'afar | F | 51 |
The University of Nottingham
| 4 years |
Adil Mohamed Hassan Taqi | M | 53 |
The University of Nottingham
| 4 years |
Kamal bin Khalid | M | 53 |
The University of Nottingham
| 3 years |
Paul Mascaro | M | - |
The University of Nottingham
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 65 | 65.00% |
Switzerland | 35 | 35.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan Terrett
- Personal Network